Latest News & Features
Americas
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports. 9 August 2016
Americas
Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione. 4 August 2016
Americas
The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case. 2 August 2016
Europe
The European Patent Office has announced several reforms to its patent opposition procedures. Stephanie Pilkington and Ling Zhuang of Potter Clarkson consider some of their implications for centralised patent revocation in Europe from a life sciences perspective. 28 July 2016
Biotechnology
In order to be well prepared before a generic or biosimilar marketing authorisation is approved, drugs companies in the EU may consider monitoring pending applications, says Ruth Franken of Hogan Lovells. 26 July 2016
Americas
Despite the clamour for more guidance on the scope and application of the Mayo test on patent eligibility, the US Supreme Court denied Sequenom’s petition in its dispute with Ariosa, as Stephen Stout and Rachael McClure of Vinson & Elkins explain. 21 July 2016
Africa
Everyone benefits from an efficiently run clinical drug study, including sponsors, contract research organisations, the investigator sites where patients are treated and observed, and most of all, patients, says Charlie Nicholson of Premier Research. 19 July 2016
Big Pharma
For many of the key questions relating to the grant of SPCs, there is some variance in the practice of national patent offices, even where there is guidance from the CJEU, as Simon Spink and Adrian Chew of Bristows explain. 14 July 2016
Asia-Pacific
Several legislative changes affecting data exclusivity of biologic drugs in Vietnam are poised to come into effect, and companies operating in this sector should take note now, as Hien Thi Thu Vu and Huong Lan Nguyen of Tilleke & Gibbins explain. 14 July 2016
Asia-Pacific
Legislative developments surrounding supplementary protection certificates in the EU are moving fast, and may be catching on as far afield as Australia. Gareth Morgan of Olswang explains more. 7 July 2016